相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1
Robert C. Carlisle et al.
BLOOD (2009)
CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies
S. S. Seregin et al.
GENE THERAPY (2009)
Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo
Jie Tian et al.
JOURNAL OF VIROLOGY (2009)
Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region
A. Danielsson et al.
CANCER GENE THERAPY (2008)
Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors
D. M. Appledorn et al.
GENE THERAPY (2008)
The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer
E. Wisse et al.
GENE THERAPY (2008)
Clearance of Adenovirus by Kupffer Cells Is Mediated by Scavenger Receptors, Natural Antibodies, and Complement
Zhili Xu et al.
JOURNAL OF VIROLOGY (2008)
Current status of gene therapy in Asia
Sunyoung Kim et al.
MOLECULAR THERAPY (2008)
Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression
Sean E. Hofherr et al.
MOLECULAR THERAPY (2008)
Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies
Andreas Wortmann et al.
MOLECULAR THERAPY (2008)
Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide
Florian Kreppel et al.
MOLECULAR THERAPY (2008)
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
J. Nemunaitis et al.
CANCER GENE THERAPY (2007)
Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition
Bert J. C. Janssen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration
Jian-Qing Gao et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Oncolytic viruses in cancer therapy
Markus J. V. Vaha-Koskela et al.
CANCER LETTERS (2007)
Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia
Sean E. Hofherr et al.
HUMAN GENE THERAPY (2007)
Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer
Svend O. Freytag et al.
MOLECULAR THERAPY (2007)
Clinical trials with oncolytic adenovirus in China
Wang Yu et al.
CURRENT CANCER DRUG TARGETS (2007)
Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system
Anne Kiang et al.
MOLECULAR THERAPY (2006)
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin
Madan Katragadda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
Eric J. Small et al.
MOLECULAR THERAPY (2006)
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery
Mark Lyons et al.
MOLECULAR THERAPY (2006)
The erythrocyte viral trap: Transgenic expression of viral receptor on erythrocytes attenuates coxsackievirus B infection
DR Asher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors
F Kreppel et al.
MOLECULAR THERAPY (2005)
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein
SM Sumida et al.
JOURNAL OF IMMUNOLOGY (2005)
A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1)
A Repik et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers
ZH Peng
HUMAN GENE THERAPY (2005)
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses
H Mok et al.
MOLECULAR THERAPY (2005)
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States
E Nwanegbo et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2004)
The innate immune response to adenovirus vectors
DA Muruve
HUMAN GENE THERAPY (2004)
Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-Ad antibodies
H Jiang et al.
MOLECULAR THERAPY (2004)
Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses
GG Vecil et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions
JF Dong et al.
BLOOD (2002)
Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes
CT Garnett et al.
JOURNAL OF VIROLOGY (2002)
A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations
F Kreppel et al.
HUMAN GENE THERAPY (2002)
The complement response against an oncolytic virus is species-specific in its activation pathways
H Wakimoto et al.
MOLECULAR THERAPY (2002)
Complement activation by recombinant adenoviruses
G Cichon et al.
GENE THERAPY (2001)
Blood clearance rates of adenovirus type 5 in mice
R Alemany et al.
JOURNAL OF GENERAL VIROLOGY (2000)
Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions
MA Croyle et al.
HUMAN GENE THERAPY (2000)
分享论文
